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ABSTRACT  
Liquid filled hard gelatin capsule are well recognized as a solid dosage form for convenient administration of drugs orally in a liquid form. This 
liquid composition available help the most challenging drug compounds in capsules has increased significantly in recent years. The drugs which 
have low solubility, poor bioavailability, low melting point, critical stability are the perfect candidate for liquid filling in capsule. The current 
study presents the formulation aspects, filling and sealing aspects of capsule, evaluation parameters of the liquid filled hard gelatin capsule 
using Febuxostat as drug, oils (Arachis oil, Coconut oil, Olive oil) as solvents, Glyceryl monostearate as solubilizing agent, Butylated hydroxy 
toluene as antioxidant, Methyl paraben & Propyl paraben as preservatives. A capsule formed F3 formulation shows maximum drug release and 
drug content among all the formulations. 
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INTRODUCTION 
Liquid filled hard gelatin capsule are well recognized as a 
solid dosage form for convenient administration of drugs 
orally in a liquid form. Liquid filled capsule technology can be 
used for liquid and semisolid fills in hard gelatin or HPMC 
capsule with or without banding. This liquid composition 
available help the most challenging drug compounds in 
capsules has increased significantly in recent years. In 
particular it is possible to solubilize many drug compounds 
in a micro emulsion pre-concentrate inside the hard gelatin 
capsules such that on subsequent dispersion in the gastro 
intestinal tract, the drug remains in solution. It is considered 
that this technology can make a significant contribution to 
the development of efficacious pharmaceutical products by 
providing the flexibility to rapidly develop and test in – 
house formulation when small quantities of drug is available. 
Liquid-fill hard gelatin capsule technology was established in 
the early 1980s as an alternative to soft gelatin capsules This 
technology is mostly suitable for insoluble compounds, 
highly potent compounds. Once the capsule is filled, they are 
sealed by spraying small amount of Water/ethanol mixture 
at the cap and body interface followed by gentle warming to 
fuse the two parts of capsule together or by band sealing of 
capsule with gelatin or cellulose.1 
Febuxostat is a novel drug which is developed for the 
treatment of gout and hyperuricemia. As an inhibitor of 
xanthine oxidase, it provides a selective and potent property 
compared with allopurinol.2 FXT acquired admission from 
the Food and Drug Administration (FDA) in 2009.It was the 
ﬁrst new drug the FDA approved in 40 years, which was used 
for lowering the level of serum uric acid in vivo.3 In recent 
years FXT has acquired extensive attractions owing to its 
good therapeutic effect. FXT is a weak acid (PKa 3.42)4 which 
is practically insoluble in water and the solubility was about 
12.9 μg/ml in water at 37 °C.5 The bioavailability of FXT is 
approximately 80% and the half-life is about 5–8 hrs.6 FXT is 
classiﬁed as a Biopharmaceutics Classiﬁcation System (BCS) 
II drug due to its low solubility and high permeability.7 In 
general, the primary problem of formulation for BCS II drugs 
is how to improve the dissolution. Water solubility is the 
main factor that inﬂuences the bioavailability of this kind of 
drug.8 Although FXT shows good pharmaceutical behavior, 
the improvement of aqueous solubility would be conducive 
to the absorption process.9 Poor aqueous solubility could be 
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improved in many ways, such as nanosuspension, solid 
dispersion, co-crystals, hydrates and salts, liquid 
formulations using oil as solvent.10-12 The purpose of the 
present study was to provide a novel way to improve the 
aqueous solubility and in vivo bioavailability of FXT.  
Drug categories suitable for Liquid filled capsules 
1. Drugs with Poor bioavailability: 
The bioavailability of the poorly water-soluble drugs can be 
significantly enhanced when formulated as a liquid in a hard 
gelatin capsule. 13,14 
2. Drugs with Low melting point:  
Materials having low melting points or are liquid at room 
temperature have some problems when formulating as dry 
powders, often requiring high concentrations of excipient to 
avoid processing problems. 15 
3. Potent drugs:   
Drugs in this category present two main challenges; content 
uniformity and cross-contamination and worker protection. 
16,17 
4. Sustained release drug candidates:  
By choosing an appropriate excipient the release rate of an 
active ingredient can be modified. E.g., soybean oil and 
glyceryl monostearate. 18  
The objective of study was to prepare Liquid filled hard 
gelatin capsule of Febuxostat which can be useful in Gout 
therapy. Liquid filled hard gelatin capsule prepared by 
simple mixing oils (Arachis oil, Coconut oil, Olive oil), 
Glyceryl monostearate, Butylated hydroxy toluene, Methyl 
paraben & Propyl paraben as preservatives and filled into 
capsule of size 00. It was sealed by banding technique using 
15% w/v gelatin solution. The prepared capsules were 
evaluated for weight variation, content uniformity, 
disintegration, dissolution studies, release kinetics and 
stability studies. The formulation was compared with 
marketed formulation of Febuxostat (Febucip 40). 
 
Figure 1. Reasons for Formulating Drugs as Liquid 
Dosage 
MATERIALS & METHODS 
Febuxostat as a gift sample from Ami Lifesciences, Vadodara, 
Arachis oil from Modern industries, Sinnar, Olive oil from 
Evonik, Kolkata, Coconut oil, GMS from LOBA CHEMIE PVT 
LTD, Mumbai, BHT, Methyl & Propyl paraben from Research 
lab fine chem industries, Mumbai. 
Preparation of Liquid filled hard gelatin capsule  
Weigh Febuxostat 40mg and dissolved in 1ml Arachis, 
Coconut & Olive oil. Add GMS, BHT, Methyl & Propyl paraben. 
Prepared formulation was filled into capsule size 00. The 
capsule was sealed by banding technique using 15% w/v 
gelatin solution. 
 
Table 1. Composition of Febuxostat Liquid filled Hard gelatin Capsule 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Febuxostat 
(mg) 
40 40 40 40 40 40 40 40 40 
   Arachis Oil 
         (ml) 
1 1 1 - - - - - - 
   Coconut Oil 
         (ml) 
- - - 1 1 1 - - - 
Olive Oil 
         (ml) 
- - - - - - 1 1 1 
         GMS 
          (mg) 
10 15 20 10 15 20 10 15 20 
       BHT 
        (mg) 
1 1 1 1 1 1 1 1 1 
Methyl:Propyl          
Paraben (mg) 
  0.2 
(1:1) 
0.2 
(1:1) 
0.2 
(1:1) 
0.2 
(1:1) 
0.2 
(1:1) 
0.2 
(1:1) 
0.2 
(1:1) 
0.2 
(1:1) 
0.2 
(1:1) 
 
Evaluation parameters of liquid filled capsules 
19,20,21,22,23,24,25,26 
1. Weight variation test 
Fill the capsule shell with formulation. Take 20 capsules and 
weight of individual capsule should be noted and average 
weight is calculated. Not more than two individual weight 
deviates from average weight. (15) 
 2.Content uniformity:  
Intact capsule was weighed. The capsule was opened 
without losing any part of the shell and contents were 
removed as completely as possible. The shell was washed 
with ether or other suitable solvent and the shell allowed to 
stand until the odour of the solvent was no longer 
detectable. By using UV Spectroscopy content uniformity 
was calculated. 
3. Disintegration:  
The capsules were placed in the basket rack assembly, which 
is repeatedly immersed 30 times per minute into a 
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thermostatically controlled fluid at 370C. To fully satisfy the 
test, the capsules should disintegrate completely into a soft 
mass having no palpably firm core without any fragments of 
the gelatin shell. If one or two capsules fail the test should be 
repeated for additional of 12 capsules. Then not fewer than 
16 of the total 18 capsules tested should disintegrate 
completely. 
4. Dissolution studies:   
Dissolution is a process by which the disintegrated solid 
solute converted into solution. The test determines the time 
required for a definite percentage of the drug in capsules to 
dissolve under specified conditions. The release of drug was 
determined using a dissolution apparatus of USP type II 
paddle at 50 rpm 900 ml of 0.1 N HCl solution was used as a 
dissolution media and maintained at temp 37.50C for 60 min. 
The dissolution study of liquid filled hard gelatin capsule 
was compared with marketed formulation of Febuxostat 
(Febucip 40). The data was subjected for kinetic model. The 
kinetic modeling of drug release and the model with the 
higher correlation coefficient i.e. higher R2 was considered to 
be the best fit model. 
5.Stability studies:   
Preliminary stability of the best formulation obtained by 
investigating its Physical characteristics and drug content 
and drug release after storage at stressed conditions. LFHGC 
was stored at 40±20C & 75±5% RH for a period of 1 month. 
The Physical characteristics and drug content and drug 
release of the fresh (stored at room temperature) and 
stressed preparations are compared to evaluate the stability 
and effect of aging.  
RESULT AND DISCUSSION 
1. Weight variation 
The weight of each liquid filled capsule was taken on 
Electronic analytical balance and the weight variation was 
calculated as mean SD. Weight variation varies from 
98.60±0.945 to 102.3 ±2.210. 
2. Content uniformity: 
Drug content of optimized batches were calculated by using 
liquid filled capsule containing 40 mg of febuxostat. Three 
trials from each formulation are analyzed 
spectrophotometrically. The mean value and standard 
deviation of all the formulations are calculated. The drug 
content ranging from 97.05±2.155 to 99.31 ±2.455. The 
results indicated that in all the formulations the drug 
content is uniform. The studies also show that uniformity of 
content is in the range of 85-115%. 
3. Disintegration: 
The capsules were placed in the basket rack assembly, which 
is repeatedly immersed 30 times per minute into a 
thermostatically controlled fluid at 370C. To fully satisfy the 
test, the capsules should disintegrate completely into a soft 
mass having no palpably firm core without any fragments of 
the gelatin shell. Limit of disintegration is 30 min. The 
disintegration time ranging from 33.0 ± 0.535 to 
38.0±1.1305. The result indicated that all the formulations 
shows very less deviation in disintegration profile which 
may be because of the same size & type of capsule shell used.  
4. Dissolution studies  
The release of drug was determined using a dissolution 
apparatus of USP type II paddle at 50 rpm 900 ml of 0.1 N 
HCl solution was used as a dissolution media and maintained 
at temp 37.50C for 60 min. In-vitro dissolution study shows 
% cumulative drug release ranging from 80.10±0.80 to 
98.57±0.993. Maximum release i.e. 98.57% for F3 
formulation this could be attributed due to higher 
concentration of GMS in the formulation.  
In vitro dissolution profile of liquid filled capsule (F3) and 
Marketed formulation (Febucip 40) are compared together. 
Liquid filled capsule of febuxostat shows more % drug 
release than the marketed formulation which may be 
because of undissolved amount of the drug present in 
marketed formulation even after 60 min.   
5. Kinetics of drug release: 
To analyze the mechanism of drug release of the optimized 
batch (F3) of the liquid filled hard gelatin capsule was 
obtained from the drug release studies which was subjected 
to mathematical model of korsemeyer’s peppas. The 
correlation coefficient (r2) was used as an indicator for the 
best fitting for each of the models. The table 7 shows the 
Kinetics treatment for the optimized formulation(F3). The 
drug release mechanism of liquid filled hard gelatin capsule 
of febuxostat was shown below. 
6. Stability studies: 
 Optimized formulation F3 at 40± 2oC, 75 ± 5 % RH was 
found to be stable up to 30 days. There was no significant 
change in drug content, visual appearance i.e. changes in 
color. All Formulations stored at elevated temperature 
showed very slight changes in disintegration time and drug 
content and drug release. 
  
Table 2. Evaluation of Febuxostat Liquid filled Hard gelatin Capsule 
Sr.No. Formulation 
code 
Average weight 
(mg) 
Mean ± SD 
Drug content 
(%) 
Mean ±SD 
Disintegration 
time (min)  
Mean ±S.D. 
01 F1 98.70±0.807  97.10±2.160 36.7 ± 1.141 
02 F2 99.0 ±0.894 98.35 ±2.350 34.2 ± 0.580 
03 F3 98.60±0.945 99.31 ±2.455 33.0 ± 0.535  
04 F4 101.75±1.512 97.05 ±2.155  37.3 ± 1.230  
05 F5 100.5±1.554 98.20 ±2.310 35.0 ± 0.860 
06 F6 102.10±1.575 99.08 ±2.425 33.3 ± 0.550  
07 F7 101.0±2.120 97.40 ±2.425 38.0±1.1305 
08 F8 102.3±2.210 98.71 ±2.390 35.5±0.875 
09 F9 99.5 ±2.090 99.15 ±2.433 33.1±0.400 
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Table 3. Dissolution study of liquid filled hard gelatin capsule of Febuxostat 
 
 
Table.4: In vitro dissolution profile of liquid filled capsule (F3) and Marketed formulation (Febucip 40) 
 
Sr.no. 
 
Time (min) 
 
 
% Drug Release 
  Liquid filled capsule 
(F3) 
Marketed formulation 
(Febucip 40) 
1 10               61.53 28.524 
2 20               77.85 35.690 
3 30               84.21 46.327 
4 40               90.65 59.016 
5 50               94.85 68.128 
6 60               98.57 70.269 
 
Table 5. R2 values for Korsemeyer's peppas release kinetics 
 
 
 
                       Formulation Code          F3 
                    R2 value           0.985 
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Table 6. Stability data for F3 formulation 
SR. 
NO 
OBSERVATION BERFOR STABILITY 
TESTING 
AFTER STABILITY 
TESTING 
 
1. 
 
 
Visual appearance 
(Color changes) 
 
No change 
 
No change 
 
2. 
 
Drug content 
 
99.31% 
 
99.28% 
 
3. 
 
Disintegration time 
 
33 min 
 
34 min 
 
4 
 
Drug release 
 
98.57% 
 
98.45% 
 
CONCLUSION 
Liquid filled hard gelatin capsule of Febuxostat was 
prepared using different oils. The drug content & drug 
release was found to be maximum in the capsule containing 
Arachis oil & maximum concentration of Glyceryl 
monostearate (F3). From the obtained data of our 
experimentation, liquid filled hard gelatin capsule of 
Febuxostat can be a good alternative to conventional 
uncoated marketed formulation with possible 
improvements in the absorption of the drug & subsequent 
bioavailability. 
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